The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 11, Issue 9, 2005, Pages 847-855

  Karmiris, Konstantinos ^a   Koutroubakis, Ioannis E ^a   Kouroumalis, Elias A ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Adipocytokines; Adiponectin; Crohn's disease; Ghrelin; Leptin; Resistin; Ulcerative colitis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GHRELIN; LEPTIN; RESISTIN;

ADIPOCYTE; ADIPOSE TISSUE; ANOREXIA; BODY COMPOSITION; CROHN DISEASE; ENDOCRINE CELL; ENTERITIS; GENE OVEREXPRESSION; HORMONE ACTION; HUMAN; IMMUNOREGULATION; INFLAMMATION; MALNUTRITION; MEDIATOR; MESENTERIC OBESITY; MESENTERY; MESENTERY ADIPOSE TISSUE; MESENTERY DISEASE; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; ULCERATIVE COLITIS; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ADIPONECTIN; HUMANS; INFLAMMATORY BOWEL DISEASES; LEPTIN; MESENTERY; PEPTIDE HORMONES; RESISTIN;

EID: 25444436668     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mib.0000178915.54264.8f     Document Type: Review

References (133)

1. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11:327-33
2. Frayn KN, Karpe F, Fielding BA, et al. Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord. 2003;27:875-888.
3. Trayhurn P, Wood S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347-355.
4. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology. 1999;117:73-81.
5. Pond CM. Long-term changes in adipose tissue in human disease. Proc Nutr Soc. 2001;60:365-374.
6. Sanchez-Hidalgo M, Martin A, Villegas I, et al. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol. 2005;69:1733-1744.
7. Lewis JD, Lichtenstein GR, Stein RB, et al. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol. 2001;96:3323-3328.
8. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human analogue. Nature. 1994;372:425-432.
9. Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273-2282.
10. Margetic S, Gazzola C, Pegg GC, et al. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26:1407-1433.
11. Houseknecht KL, Mantzoros CS, Kuliawat R, et al. Evidence for leptin binding to proteins in serum of rodents and humans: modulation with obesity. Diabetes. 1996;45:1638-1643.
12. Hill RA, Margetic S, Pegg GG, et al. Leptin: its pharmacokinetics and tissue distribution. Int J Obes Relat Metab Disord. 1998;22:765-770.
13. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763-770.
14. Flier JS. Clinical review 94: what's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab. 1998;83:1407-1413.
15. Hellstrom P, Geliebter A, Naslund E, et al. Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects. Br J Nutr. 2004;92, Suppl.1:S47-S57.
16. Otero M, Lago R, Lago F, et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 2005;579:295-301.
17. Ballinger A. Divergency of leptin response in intestinal inflammation. Gut. 1999;44:588-589.
18. Bouloumie A, Marumo T, Lafontan M, et al. Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999;13:1231-1238.
19. Beltowski J, Wojcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinaemia. Atherosclerosis. 2003;170:21-29.
20. Nakanishi S, Yamane K, Kamei N, et al. A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metabolism. 2005;54:194-199.
21. Quehenberger P, Exner M, Sunder-Plassmann R, et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res. 2002;90:711-718.
22. Lord GM, Matarese G, Howard JK, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394:897-901.
23. Zhao Y, Sun R, You L, et al. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem Biophys Res Commun. 2003;300:247-252.
24. Sennello JA, Fayad R, Morris AM, et al. Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. Endocrinology. 2005;146:2157-2164.
25. Zarkesh-Esfahani H, Pockley G, Metcalfe RA, et al. High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol. 2001;167:4593-4599.
26. Caldefie-Chezet F, Poulin A, Tridon A, et al. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action? J Leukoc Biol. 2001;69:414-418.
27. Dixit VD, Mielenz M, Tabu DD, et al. Leptin induces growth hormone secretion from peripheral blood mononuclear cells via a protein kinase C- and nitric oxide-dependent mechanism. Endocrinology. 2003;144:5595-5603.
28. Grunfield C, Zhao C, Fuller J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest. 1996;97:2152-2157.
29. Janik JE, Curti BD, Considine RV, et al. Interleukin 1 alpha increases serum leptin levels in humans. J Clin Endocrinol Metab. 1997;82:3084-3086.
30. Zumbach MS, Boehme MW, Wahl P. Tumor necrosis factor increases serum leptin levels in humans. J Clin Endocrinol Metab. 1997;82:4080-4082.
31. Barbier M, Cherbut C, Aube AC, et al. Elevated plasma leptin concentration in early stages of experimental intestinal inflammation in rats. Gut. 1998;43:783-790.
32. Hultgren OH, Ohman L, Hultgren Hornquist E. Decreased leptin production in mice after onset of ulcerative colitis-like disease. Scand J Gastroenterol. 2004;39:1166-1167.
33. Cakir B, Bozkurt A, Ercan F, et al. The anti-inflammatory effect of leptin on experimental colitis: involvement of endogenous glucocorticoids. Peptides. 2004;25:95-104.
34. Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab. 2005;90:3510-3516.
35. Barbier M, Vidal H, Desreumaux P, et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol. 2003;27:987-991.
36. Tuzun A, Uygun A, Yesilova Z, et al. Leptin levels in the acute stage of ulcerative colitis. J Gastroenterol Hepatol. 2004;19:429-432.
37. Hoppin AG, Kaplan LM, Zurakowski D, et al. Serum leptin in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998;26:500-505.
38. Ballinger A, Kelly P, Hallyburton E, et al. Plasma leptin in chronic inflammatory bowel disease and HIV infection: implications for the pathogenesis of anorexia and weight loss. Clin Sci. 1998;94:479-483.
39. Sitaraman S, Liu X, Charrier L, et al. Colonic leptin: source of a novel proinflammatory cytokine involved in IBD. FASEB J. 2004;18:696-698.
40. Siegmund B, Sennello JA, Jones-Carson J, et al. Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice. Gut. 2004;53:965-972.
41. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221:286-289.
42. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol. 1998;8:335-338.
43. Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26:2442-2450.
44. Gavrila A, Peng CK, Chan JL, et al. Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab. 2003;88:2838-2843.
45. Viengehareun S, Zennaro MC, Pascual-Le Tallec L, et al. Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. FEBS Lett. 2002;532:345-350.
46. Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab. 2002;87:5662-5667.
47. Delporte ML, Funahashi T, Takahashi M, et al. Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J. 2002;367:677-685.
48. Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003;301:1045-1050.
49. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167-175.
50. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit. 2003;9:RA55-RA61.
51. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86:3815-3819.
52. Pannacciulli N, Vettor R, Milan G, et al. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab. 2003;88:1748-1752.
53. Kern PA, Di Gregorio GB, Lu T, et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003;52:1779-1785.
54. Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med. 2004;10:524-529.
55. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-1295.
56. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100.
57. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54:117-121.
58. Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNFa in KK-Ay obese mice. Hepatology. 2004;40:177-184.
59. Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796-1807.
60. Chen H, Montagnani M, Funahashi T, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278:45021-45026.
61. Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity and cardiovascular disease. Biochimie. 2004;86:779-784.
62. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a c-AMP-dependent pathway. Circulation. 2000;102:1296-1301.
63. Wulster-Radcliffe MC, Ajuwon KM, Wang J, et al. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun. 2004;316:924-929.
64. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase 1 through interleukin-10 expression in human macrophages. Circulation. 2004;109:2046-2049.
65. Soares AF, Guichardant M, Cozzone D, et al. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med. 2005;38:882-889.
66. Yamamoto K, Kiyohara T, Murayama Y, et al. Production of adiponectin, an anti- inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut. 2005;54:789-796.
67. Paul G, Fürst A, Büchler C, et al. Specific local secretion pattern of adipocytokines, cytokines and chemokines by fat tissue in Crohn's disease. Gastroenterology. 2005;128:A212.
68. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312.
69. Gabriely I, Ma XH, Yang XM. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes. 2002;51:2951-2958.
70. McTernan PG, McTernan CL, Chetty R, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab. 2002;87:2407.
71. Delhanty PJ, Mesotten D, McDougall F, et al. Growth hormone rapidly induces resistin gene expression in white adipose tissue of spontaneous dwarf (SDR) rats. Endocrinology. 2002;143:2445-2448.
72. Shojima N, Sakoda H, Ogihara T, et al. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes. 2002;51:1737-1744.
73. Fukui Y, Motojima K. Expression of resistin in the adipose tissue is modulated by various factors including peroxisome proliferator-activated receptor alpha. Diab Obes Metab. 2002;4:342-345.
74. Nogueiras R, Gualillo O, Caminos JE, et al. Regulation of resistin by gonadal, thyroid hormone and nutritional status. Obes Res. 2003;11:408-414.
75. Yuzuriha H, Inui A, Goto K, et al. Intracerebroventricular administration of NPY stimulates resistin gene expression in mice. Int J Mol Med. 2003;11:675-676.
76. Oliver P, Pico C, Serra F, et al. Resistin expression in different adipose tissue depots during rat development. Mol Cell Biochem. 2003;252:397-400.
77. Nogueiras R, Gallego R, Gualillo O, et al. Resistin is expressed in different rat tissues and is regulated in a tissue- and gender- specific manner. FEBS Lett. 2003;548:21-27.
78. Yannakoulia M, Yiannakouris N, Bluher S, et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin and resistin concentrations in healthy humans. J Clin Endocrinol Metab. 2003;88:1730-1736.
79. Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science. 2004;303:1195-1198.
80. Fasshauer M, Klien J, Neumann S, et al. Tumor necrosis alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2001;288:1027-1031.
81. Kaser S, Kaser A, Sandhofer A, et al. Resistin m-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309:286-290.
82. Rajala MW, Lin Y, Ranalletta M, et al. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol. 2002;16:1920-1930.
83. Lu SC, Shich WY, Chen CY, et al. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett. 2002;530:158-162.
84. Schaffler A, Ehling A, Neumann E, et al. Adipocytokines in synovial fluid. JAMA. 2003;290:1709-1710.
85. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87:2988-2991.
86. Korbonits M, Goldstone A, Gueorguiev M, et al. Ghrelin-a hormone with multiple functions. Front Neuroendocrinol. 2004;25:27-68.
87. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660.
88. Hosoda H, Kojima M, Matsuo H, et al. Ghrelin and des-acyl ghrelin: Two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun. 2000;279:909-913.
89. Thompson NM, Gill DA, Davies R, et al. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of GHS-R 1a. Endocrinology. 2004;145:232-242.
90. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tract of rats and humans. Endocrinology. 2000;141:4255-4261.
91. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab. 2001;86:4753-4758.
92. Sakata I, Nakamuia K, Yamazaki M, et al. Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides. 2002;23:531-536.
93. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-1630.
94. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714-1719.
95. Tschop M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest. 2001;24:RC19-RC21.
96. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002;87:240-244.
97. McCowen KC, Maykel JA, Bistrian BR, et al. Circulating ghrelin concentrations are lowered by intravenous glucose or hyperinsulinemic euglycemic conditions in rodents. J Endocrinol. 2002;175:R7-R11.
98. Asakawa A, Inui A, Kaga T, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut. 2003;52:947-952.
99. Weigle DS, Cummings DE, Newby PD, et al. Roles of leptin and ghrelin in the loss of body weight caused by a low fat, high carbohydrate diet. J Clin Endocrinol Metab. 2003;88:1577-1586.
100. Saad MF, Bernaba B, Hwu CM, et al. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab. 2002;87:3997-4000.
101. Toshinai K, Mondal MS, Nakazato M, et al. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia and leptin administration. Biochem Biophys Res Commun. 2001;281:1220-1225.
102. Ariyasu H, Takaya K, Hosoda H, et al. Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. Endocrinology. 2002;143:3341-3350.
103. Haqq AM, Faroqi IS, O'Rahilly S, et al. Serum ghrelin levels are inversely correlated with body mass index, age and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88:174-178.
104. Chan JL, Bullen J, Lee JH, et al. Ghrelin levels are not regulated by recombinant leptin administration and/or three days of fasting in healthy subjects. J Clin Endocrinol Metab. 2004;89:335-343.
105. Dass NB, Munonyara M, Bassil AK, et al. Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the affects of ghrelin. Neuroscience. 2003;120:443-453.
106. Ott V, Fasshauer M, Dalski A, et al. Direct peripheral effects of ghrelin include suppression of adiponectin expression. Horm Metab Res. 2002;34:640-645.
107. th Annual Meeting of the Endocrine Society. 2003;OR51-3.
108. Peracchi M, Conte D, Terrani C, et al. Circulating ghrelin levels in celiac patients. Am J Gastroenterol. 2003;98:2474-2478.
109. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha - direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
110. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-a. Cytokine Growth Factor Rev. 2003;14:447-455.
111. Prins JB, Niesler CU, Winterford CM, et al. Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes. 1997;46:1939-1944.
112. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196-4200.
113. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278-301.
114. Fruhbeck G. The adipose tissue as a source of vasoactive factors. Curr Med Chem Cardiovasc Hematol Agents. 2004;2:197-208.
115. Bruun JM, Pedersen SB, Richelsen B. Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab. 2001;86:1267-1273.
116. Starnes T, Broxmeyer HE, Robertson M, et al. Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol. 2002;169:642-646.
117. Lundgren CH, Brown SL, Nordt TK, et al. Elaboration of type-1 plasminogen activator inhibitor from adipocytes - a potential pathogenetic link between obesity and cardiovascular disease. Circulation. 1996;93:106-110.
118. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. New Engl J Med. 1999;340:448-454.
119. Koutroubakis IE. Unravelling the mechanisms of thrombosis in inflammatory bowel disease. Am J Gastroenterol. 2001;96:1325-1327.
120. Desreumaux P, Huet G, Zerimech F, et al. Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease. Eur J Gastroenterol Hepatol. 1999;11:1113-1119.
121. Oller do Nascimento C, Hunter L, Trayhurn P. Regulation of haptoglobin gene expression in 3T3-L1 adipocytes by cytokines, catecholamines, and PPARγ. Biochem Biophys Res Commun. 2004;313:702-708.29
122. Fain JN, Bahouth SW, Madan AK. Haptoglobin release by human adipose tissue in primary culture. J Lipid Res. 2004;45:536-542.
123. Lubega J, Davies TJ. A comparison of serum mucoprotein with serum alpha 1 acid glycoprotein, haptoglobin, and alpha 1 antitrypsin assays in monitoring inflammatory bowel disease. Clin Chim Acta. 1990;188:59-69.
124. Lin Y, Rajala MW, Berger JP, et al. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem. 2001;276:42077-42083.
125. Chambers RE, Stross P, Barry RE, et al. Serum amyloid A protein compared with C- reactive protein, alpha 1 -antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest. 1987;17:460-467.
126. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112:1785-1788.
127. Reinecker HC, Loh EY, Ringler DJ, et al. MCP-1 gene expression in intestinal epithelial cells and IBD mucosa. Gastroenterology. 1995;108:40-50.
128. Kalant D, Cain SA, Maslowska M, et al. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J Biol Chem. 2003;278:11123-11129.
129. Ouchi N, Kihara S, Funahasi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671-674.
130. Yudkin JS, Kumari M. Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-214.
131. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661-665.
132. Peeraully MR, Jenkins JR, Trayhum P. NGF gene expression and secretion in white adipose tissue: regulation in 3T3-L1 adipocytes by hormones and inflammatory cytokines. Am J Physiol Endocrinol Metab. 2004;287:E331-E339.30
133. Vega JA, Garcia-Suarez O, Hannestad J, et al. Neurotrophins and the immune system. J Anat. 2003;203:1-19.